tiprankstipranks
Sartorius Stedim Biotech Revises 2024 Guidance
Company Announcements

Sartorius Stedim Biotech Revises 2024 Guidance

Sartorius Stedim Biotech (FR:DIM) has released an update.

Don't Miss Our Christmas Offers:

Sartorius Stedim Biotech, amid a volatile market, reports a slight decline in sales revenue by 1.2% in constant currencies for H1 2024, adjusting its full-year guidance to prior-year levels. The company sees a decrease in underlying EBITDA by 6.8% and a more conservative outlook due to mixed industry demand and geopolitical uncertainties, despite a robust equity ratio and reduced net debt. They maintain positive long-term prospects for the life science and biopharmaceutical markets without altering their medium-term targets up to 2028.

For further insights into FR:DIM stock, check out TipRanks’ Stock Analysis page.

Related Articles
Howard Kim0RG8 Upcoming Earnings Report: What to Expect?
TipRanks European Auto-Generated NewsdeskSartorius Stedim Biotech Reports H1 2024 Results
TipRanks European Auto-Generated NewsdeskSartorius Stedim Biotech Adjusts 2024 Outlook
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App